Testing two doses of everolimus for neuroendocrine tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed neuroendocrine tumor (NET) that is well-differentiated (low or intermediate grade) and started in the gastrointestinal tract, pancreas, lung, or unknown origin.
- Your cancer is advanced (spread or cannot be removed by surgery) and can be seen on scans.
- Your disease has gotten worse in the last 6 months (as shown by scans).
- You have already tried at least one other type of cancer treatment (stopped more than 3 weeks ago).
- You are in fairly good overall health (ECOG score 0-2) and your blood counts, liver, and kidney function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
This trial tests the combination of everolimus (a targeted pill) with a PD-1 immunotherapy drug for people with advanced colorectal cancer that has a specific gene change (PTEN mutation). The goal is to see if this two-drug approach works better than standard treatments for cancers that have stopped responding to chemotherapy.
This trial tests whether adding lenvatinib (a targeted cancer drug) to everolimus (an immunosuppressant that fights cancer) works better than everolimus alone for advanced bone cancers like osteosarcoma, Ewing sarcoma, or chondrosarcoma that have progressed despite prior chemotherapy.
This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.